The clinical-stage biotech Cocrystal Pharma is developing a single treatment that targets the essential parts of the proteins a virus needs to replicate, meaning it could one day be used across multiple viruses. Its lead candidate, CDI-988, is in development for both norovirus and coronavirus. Cocrystal’s CDI-988 is a pan-viral protease inhibitor. The company completed a Phase…
